Literature DB >> 18803326

How does the Schwann cell lineage form tumors in NF1?

Steven L Carroll1, Nancy Ratner2.   

Abstract

Neurofibromas are benign tumors of peripheral nerve that occur sporadically or in patients with the autosomal dominant tumor predisposition syndrome neurofibromatosis type 1 (NF1). Multiple neurofibroma subtypes exist which differ in their site of occurrence, their association with NF1, and their tendency to undergo transformation to become malignant peripheral nerve sheath tumors (MPNSTs), the most common malignancy associated with NF1. Most NF1 patients carry a constitutional mutation of the NF1 tumor suppressor gene. Neurofibromas develop in these patients when an unknown cell type in the Schwann cell lineage loses its remaining functional NF1 gene and initiates a complex series of interactions with other cell types; these interactions may be influenced by aberrant expression of growth factors and growth factor receptors and the action of modifier genes. Cells within certain neurofibroma subtypes subsequently accumulate additional mutations affecting the p19(ARF)-MDM2-TP53 and p16INK4A-Rb signaling cascades, mutations of other as yet unidentified genes, and amplification of growth factor receptor genes, resulting in their transformation into MPNSTs. These observations have been validated using a variety of transgenic and knockout mouse models that recapitulate neurofibroma and MPNST pathogenesis. A new generation of mouse models is also providing important new insights into the identity of the cell type in the Schwann cell lineage that gives rise to neurofibromas. Our improving understanding of the mechanisms underlying the pathogenesis of neurofibromas and MPNSTs raises intriguing new questions about the origin and pathogenesis of these neoplasms and establishes models for the development of new therapies targeting these neoplasms.

Entities:  

Mesh:

Year:  2008        PMID: 18803326      PMCID: PMC2652636          DOI: 10.1002/glia.20776

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   8.073


  134 in total

Review 1.  Pathophysiology of neurofibromatosis type 1.

Authors:  Amy Theos; Bruce R Korf
Journal:  Ann Intern Med       Date:  2006-06-06       Impact factor: 25.391

2.  Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours.

Authors:  C T Storlazzi; H R Brekke; N Mandahl; O Brosjö; S Smeland; R A Lothe; F Mertens
Journal:  J Pathol       Date:  2006-08       Impact factor: 7.996

3.  Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts.

Authors:  L S Sherman; R Atit; T Rosenbaum; A D Cox; N Ratner
Journal:  J Biol Chem       Date:  2000-09-29       Impact factor: 5.157

4.  Glioma formation in neurofibromatosis 1 reflects preferential activation of K-RAS in astrocytes.

Authors:  Biplab Dasgupta; Wen Li; Arie Perry; David H Gutmann
Journal:  Cancer Res       Date:  2005-01-01       Impact factor: 12.701

5.  Malignant schwannoma-derived cells support human skin mast cell survival in vitro.

Authors:  T Demitsu; S Murata; M Kakurai; T Kiyosawa; H Yaoita
Journal:  J Dermatol Sci       Date:  1998-01       Impact factor: 4.563

6.  Rescue of a Drosophila NF1 mutant phenotype by protein kinase A.

Authors:  I The; G E Hannigan; G S Cowley; S Reginald; Y Zhong; J F Gusella; I K Hariharan; A Bernards
Journal:  Science       Date:  1997-05-02       Impact factor: 47.728

7.  Expression of the human hematopoietic progenitor cell antigen CD34 in vascular and spindle cell tumors.

Authors:  P R Cohen; R P Rapini; A I Farhood
Journal:  J Cutan Pathol       Date:  1993-02       Impact factor: 1.587

8.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1.

Authors:  T Jacks; T S Shih; E M Schmitt; R T Bronson; A Bernards; R A Weinberg
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

9.  TP53 mutations are frequent in malignant NF1 tumors.

Authors:  E Legius; H Dierick; R Wu; B K Hall; P Marynen; J J Cassiman; T W Glover
Journal:  Genes Chromosomes Cancer       Date:  1994-08       Impact factor: 5.006

10.  Angiogenic and invasive properties of neurofibroma Schwann cells.

Authors:  S Sheela; V M Riccardi; N Ratner
Journal:  J Cell Biol       Date:  1990-08       Impact factor: 10.539

View more
  63 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

3.  Efficient generation of schwann cells from human embryonic stem cell-derived neurospheres.

Authors:  Lina Ziegler; Sergei Grigoryan; In Hong Yang; Nitish V Thakor; Ronald S Goldstein
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

4.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

5.  Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Authors:  Syed J Kazmi; Stephanie J Byer; Jenell M Eckert; Amy N Turk; Richard P H Huijbregts; Nicole M Brossier; William E Grizzle; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Am J Pathol       Date:  2013-01-13       Impact factor: 4.307

6.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

Review 7.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

8.  Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.

Authors:  Adrienne L Watson; Eric P Rahrmann; Branden S Moriarity; Kwangmin Choi; Caitlin B Conboy; Andrew D Greeley; Amanda L Halfond; Leah K Anderson; Brian R Wahl; Vincent W Keng; Anthony E Rizzardi; Colleen L Forster; Margaret H Collins; Aaron L Sarver; Margaret R Wallace; Stephen C Schmechel; Nancy Ratner; David A Largaespada
Journal:  Cancer Discov       Date:  2013-03-27       Impact factor: 39.397

Review 9.  Mouse models of cancer: Sleeping Beauty transposons for insertional mutagenesis screens and reverse genetic studies.

Authors:  Barbara R Tschida; David A Largaespada; Vincent W Keng
Journal:  Semin Cell Dev Biol       Date:  2014-01-24       Impact factor: 7.727

10.  Translationally controlled tumor protein is a novel biological target for neurofibromatosis type 1-associated tumors.

Authors:  Daiki Kobayashi; Mio Hirayama; Yoshihiro Komohara; Souhei Mizuguchi; Masayo Wilson Morifuji; Hironobu Ihn; Motohiro Takeya; Akira Kuramochi; Norie Araki
Journal:  J Biol Chem       Date:  2014-08-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.